ClinicalTrials.gov
public full text
Public Domain
Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and 12-week administration of USP methylene blue (MB) on cerebral blood flow, functional connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Amyloid Accumulation After Mild Traumatic Brain Injury#900288
- Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)#848510
- Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.#345145
- Silver nanoparticles and neurotoxicity: mechanistic insights and recent experimental evidence#301072
- EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors#876019
Record · ID 1126560
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive